DSG Capital Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$38.6M Sell
33,507
-421
-1% -$430K 5.48% 3
2026
Q1
$31.2M Sell
33,928
-1,011
-3% -$1.02M 4.99% 3
2025
Q4
$36.1M Sell
34,939
-359
-1% -$343K 5.5% 5
2025
Q3
$26.9M Buy
35,298
+4,843
+16% +$3.6M 4.29% 4
2025
Q2
$23.7M Buy
30,455
+1,193
+4% +$927K 4.22% 4
2025
Q1
$24.2M Buy
29,262
+32
+0.1% +$26.6K 4.88% 4
2024
Q4
$22.6M Buy
+29,230
New +$24.2M 4.09% 5

Other funds holding LLY

DSG Capital Advisors's LLY Position: Q2 2026 in Review

DSG Capital Advisors reduced its Eli Lilly (LLY) stake by 1.2% in Q2 2026, selling an estimated $430K and leaving 33,507 shares worth $38.6M. The position accounts for 5.48% of the portfolio, ranked #3.

DSG Capital Advisors first reported a position in LLY in Q4 2024 and has held it in 7 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • DSG Capital Advisors held 33,507 shares of Eli Lilly worth $38.6M as of Q2 2026.
  • DSG Capital Advisors sold 421 Eli Lilly shares in Q2 2026, an estimated $430K.
  • Eli Lilly made up 5.48% of DSG Capital Advisors's portfolio in Q2 2026, its #3 holding.
  • DSG Capital Advisors first reported a position in Eli Lilly in Q4 2024 and has held it in 7 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on DSG Capital Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.